{'fraction_non_alphanumeric': 0.020766773162939296, 'fraction_numerical': 0.001597444089456869, 'mean_word_length': 5.8469945355191255, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
L‐carnitine ameliorate podocyte injury in diabetic nephropathy by increasing the glucose uptake

High glucose could change podocyte gene expression and subsequently induce podocyte damage through altered glucose metabolism. L‐carnitine is known to play a beneficial role in diabetes, however, there are no studies on the effect of L‐carnitine on podocyte alteration in high glucose condition. This study was to investigate whether L‐carnitine can attenuate diabetic podocyte injury through the prevention of slit diaphragm proteins loss. L‐carnitine treatment group showed an increased glucose uptake compared to control group, suggesting that utilization of glucose in the podocyte increased by L‐carnitine. L‐carnitine treatment also prevented the decreased mRNA expressions of nephrin and podocin in high glucose‐stimulated podocytes. However, the mRNA expression of CD2AP and ¥á‐actinin‐4 were not significantly changed by high glucose condition. Taken together, L‐carnitine could increase glucose uptake of podocyte in high glucose condition and its mechanism may be at least partly related to the upregulation of nephrin and podocin. Our results give information on the understanding the beneficial effects of L‐carnitine in diabetic nephropathy.